Prescribing for Dry Eye Disease - Summary - MDSpire

Prescribing for Dry Eye Disease

The Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III report, which was recently released, includes an updated prescribing algorithm based on DED etiology or pathogenic drivers.

  • By

  • LISA HORNICK, OD, MBA, FAAO

  • July 1, 2025

  • 7 min

Share

Objective:

Emphasize the significance of the TFOS DEWS III report in shaping treatment options.

Approach:
    Key Findings:
    • Include specific examples of therapies for each driver.
    Interpretation:

    Mention implications for clinical practice.

    Limitations:
    • Specify how the lack of clinical trial data affects treatment decisions.
    Conclusion:

    Reiterate the importance of individualized treatment plans.

    Sources:

Original Source(s)

Prescribing for Dry Eye Disease

  • by LISA HORNICK, OD, MBA, FAAO

  • July 1, 2025

Related Content

Insights into the quality and guideline consistency of dry eye disease treatment videos on Chinese short-video platforms

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

LASIK’s Lingering Immune Effects

Study finds that LASIK leaves lasting corneal immune footprint

  • June 25, 2026

  • 3 min